Brevan Howard Capital Management LP Sells 23,597 Shares of Elevance Health, Inc. $ELV

Brevan Howard Capital Management LP decreased its stake in Elevance Health, Inc. (NYSE:ELV) by 66.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,874 shares of the company’s stock after selling 23,597 shares during the period. Brevan Howard Capital Management LP’s holdings in Elevance Health were worth $3,837,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Nilsine Partners LLC boosted its holdings in Elevance Health by 1.5% in the 3rd quarter. Nilsine Partners LLC now owns 1,918 shares of the company’s stock valued at $620,000 after purchasing an additional 29 shares during the period. HBK Sorce Advisory LLC increased its holdings in shares of Elevance Health by 4.4% during the 3rd quarter. HBK Sorce Advisory LLC now owns 743 shares of the company’s stock worth $260,000 after purchasing an additional 31 shares during the period. Detalus Advisors LLC increased its holdings in shares of Elevance Health by 1.8% during the 3rd quarter. Detalus Advisors LLC now owns 1,726 shares of the company’s stock worth $558,000 after purchasing an additional 31 shares during the period. Forum Financial Management LP raised its position in shares of Elevance Health by 1.1% during the third quarter. Forum Financial Management LP now owns 2,971 shares of the company’s stock valued at $960,000 after buying an additional 33 shares during the last quarter. Finally, Activest Wealth Management lifted its stake in shares of Elevance Health by 66.7% in the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after buying an additional 34 shares during the period. Institutional investors own 89.24% of the company’s stock.

Analysts Set New Price Targets

ELV has been the topic of a number of recent research reports. Robert W. Baird lifted their target price on Elevance Health from $297.00 to $340.00 and gave the stock a “neutral” rating in a research report on Thursday, December 11th. Wolfe Research set a $425.00 price objective on Elevance Health and gave the stock an “outperform” rating in a research report on Thursday, January 8th. UBS Group set a $400.00 price objective on Elevance Health in a report on Thursday, January 29th. Wall Street Zen cut Elevance Health from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $332.00 target price on shares of Elevance Health in a research note on Thursday, January 29th. Twelve research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Elevance Health has an average rating of “Moderate Buy” and an average price target of $387.40.

Elevance Health Stock Up 0.1%

ELV opened at $291.94 on Tuesday. The firm’s 50-day simple moving average is $336.82 and its 200-day simple moving average is $334.32. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 1.54. Elevance Health, Inc. has a twelve month low of $273.71 and a twelve month high of $458.75. The firm has a market cap of $64.43 billion, a price-to-earnings ratio of 11.62, a PEG ratio of 1.61 and a beta of 0.51.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.10 by $0.23. The firm had revenue of $49.31 billion during the quarter, compared to the consensus estimate of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The firm’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period last year, the firm posted $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Equities research analysts anticipate that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be paid a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.4%. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date is Tuesday, March 10th. Elevance Health’s dividend payout ratio is presently 27.39%.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.